Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy

Figures

• 

  Figure 1.. MYBPC3 nontruncating pathogenic variants cause similar phenotypic severity and adverse event rates as truncating variants. A, Distributions in maximum wall thickness demonstrate broad phenotypic variance and similarity between truncating and nontruncating MYBPC3 pathogenic variant groups. Data is shown in violin plots with median and interquartile range. B, Average age-adjusted left atrial diameter was smaller among nontruncating pathogenic variant carriers. C, Broad variability in disease severity is reflected by range in age of diagnosis in both MYBPC3 groups, with a modestly lower average age of diagnosis among nontruncating pathogenic variant carriers. D, Kaplan-Meier survival analysis shows no difference in the composite adverse event rate from time of birth between truncating and nontruncating pathogenic variant groups. Composite outcome consisted of first occurrence of any of the following: sudden cardiac death, resuscitated cardiac arrest, appropriate implantable cardioverter-defibrillator therapy, cardiac transplantation, left ventricle (LV) assist device implantation, LV ejection fraction <35%, or New York Heart Association class III/IV symptoms, atrial fibrillation…

• 

  Figure 2.. MYBPC3 truncating pathogenic variants cause similar phenotypic severity regardless of variant locus or type. A and B, Truncating MYBPC3 variants were categorized by locus quartiles within the gene to examine whether N-terminal or C-terminal truncations exert different effect sizes. No difference in extent of hypertrophy (A) or left atrial diameter (B) are observed. C and D, Four founder populations within Sarcomeric Human Cardiomyopathy Registry (SHaRe) were compared with determine whether phenotypic severity is different in the setting of these 4 distinct truncating variant types (c.742G>A=exonic splice variant, c.2373insG=frameshift, c.2827C>T=nonsense, c.2864_2865del=frameshift). No difference was observed either in the variance/distribution of hypertrophy (C) or in the magnitude of hypertrophy (D).

• 

  Figure 3.. Distribution of MYBPC3 pathogenic variants, variants of unknown significance, and common Genome Aggregation Database (gnomAD) variants relative to MyBP-C (myosin binding protein C) protein domains. Truncating MYBPC3 pathogenic variants are dispersed homogeneously throughout the gene, while nontruncating pathogenic variants exhibit clustering in the C3, C6, and C10 domains (18 of 22, 82%). Nontruncating variants of unknown significance are dispersed throughout the gene, as are gnomAD common variants (ie, allele frequency >4×10−5).

• 

  Figure 4.. Nontruncating MyBP-C (myosin binding protein C) mutant protein localizes to the myofilament for C3 and C6 domain mutants but does not incorporate into myofilaments for C10 domain mutants. To determine whether mutant MyBP-C proteins integrate normally into the myofilaments, both FLAG-tagged control and mutant constructs were cloned into an adenoviral vector that was then used to transduce neonatal rat ventricular myocytes (NRVMs). Forty-eight hours following transduction, NRVMs were immunofluorescently labeled with an anti-MyBP-C antibody to detect both endogenous and exogenously expressed MyBP-C (left column) and an anti-FLAG antibody to detect only the transduced MyBP-C (middle column). This system achieved stable integration of FLAG-control MyBP-C into myofilaments (top row) with no FLAG signal detected without viral transduction (second row). Nontruncating mutant MyBP-C for C3 and C6 domain pathogenic variants exhibited normal myofilament integration while C10 mutant MyBP-C exhibited poor or no myofilament localization.

• 

  Figure 5.. Nontruncating mutant MyBP-C (myosin binding protein C) degradation rates measured by cyclohexamide pulse chase demonstrate rapid degradation for C10 domain nontruncating mutant MyBP-C. To determine whether nontruncating MYBPC3 pathogenic variants alter protein stability, neonatal rat ventricular myocytes were transduced with adenoviral constructs expressing wild-type (WT) control and nontruncating mutant MyBP-C. Cyclohexamide was administered at 0, 30 min, 1 h, 3 h, 6 h, and 12 h to inhibit protein synthesis and MyBP-C was measured (see Methods in the Data Supplement). Data from 2 or more independent experiments performed in quadruplicate were fit to a first order exponential decay curve. The same control data (from FLAG-labeled wild-type expressed MyBP-C) is depicted on each graph (A–C). A and B, C3 and C6 mutant MyBP-C demonstrates similar degradation rates as control. C, C10 mutant MyBP-C demonstrates rapid degradation compared with control. Data is represented as mean±SEM. The calculated half-lives with 95% CIs are shown in Table 2.